Clinical Trials Logo
  1. Home
  2. Benign Prostatic Hyperplasia
  3. NCT05094947
  4. Details
NCT05094947 Clinical Trial

Intermittent Catheterization Versus Trial Without Catheter

Benign Prostatic Hyperplasia Clinical Trial

Official title:
Indwelling Urinary Catheterization Versus Clean Intermittent Catheterization for the Management of Acute Urinary Retention: Multicenter, Randomized, Controlled Clinical Trial.

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05094947
Other study ID # Moscow MSUMD
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 3, 2021
Est. completion date May 2022

Study information
Verified date August 2021
Source Moscow State University of Medicine and Dentistry
Contact Vigen Malkhasyan
Phone +7(909) 644-16-88
Email vigenmalkhasyan@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, comparative, multicenter, randomized controlled trial. The aim of this study is to compare the efficacy, safety and quality of life within patients with acute urinary retention managed by the intermittent catheterization compared or indwelling Foley catheter.

Recruitment information / eligibility
Status Recruiting
Enrollment 200
Est. completion date May 2022
Est. primary completion date March 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 21 Years to 95 Years
Eligibility Inclusion Criteria: Men with acute urinary retention due to prostatic hyperplasia Exclusion Criteria: - Patient's with serious conditions and incapacity - Previous urethral or prostate surgery. - Urethral stricture. - Urethrorrhagia. - Injuries of urethra and perineum. - Attempts of bladder catheterization within 15 days before the acute urinary retention episode. - Urinary tract infection. - Neurogenic bladder. - Chronic urinary retention with a bladder volume of more than 1 liter. - Obstructive uropathy due to the acute urinary retention.

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• intermittent catheterization
clean intermittent catheterization with catheter Nelaton
• trial without catheter
catheter Foley
Drug:
• alpha-blockers
tamsulosin, alfuzosin, doxazosin, silodosin

Locations
Country Name City State
Russian Federation Moscow state university of medicine and dentistry named after A.I. Evdokimov Moscow

Sponsors (1)
Lead Sponsor Collaborator
Moscow State University of Medicine and Dentistry

Country where clinical trial is conducted

Russian Federation, 

Outcome
Type Measure Description Time frame Safety issue
Primary Assessment of the quality of life Assessment of the quality of life according to the SF-36 questionnaire on the first, second, or third day after the start of intermittent catheterization 2 months
Secondary Assessment of the restoration of self-urination. A positive outcome is considered to be the restoration of independent urination, and the presence of no more than 150 ml of residual urine in a control study 12-24 hours after the restoration of urination. 2 months
See also
  Status Clinical Trial Phase
Recruiting NCT04807296 - Thulium Fiber Laser Enucleation of the Prostate (TFLEP) vs HoLEP With Moses Technology (m-HoLEP) N/A
Recruiting NCT05574244 - Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction N/A
Recruiting NCT04288427 - 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy N/A
Not yet recruiting NCT04245566 - Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH Phase 3
Withdrawn NCT01967251 - Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction Phase 2
Completed NCT02509975 - Safety and Efficacy of OCL 503 in Prostate Artery Embolization N/A
Completed NCT03246880 - Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients Phase 3
Completed NCT02206243 - Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia
Completed NCT02283684 - GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT Phase 4
Completed NCT01438775 - Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) Phase 3
Completed NCT01454349 - Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH) Phase 1/Phase 2
Completed NCT01152190 - A Study in Benign Prostatic Hyperplasia Phase 3
Completed NCT01139762 - A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms Phase 3
Active, not recruiting NCT00400894 - Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma N/A
Completed NCT00224133 - The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months Phase 3
Unknown status NCT00381108 - Study of the Effects of Pomegranate Tablets on Enlarged Prostates Phase 1
Completed NCT00701779 - Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia Phase 4
Terminated NCT02962674 - To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH. N/A
Active, not recruiting NCT05415748 - Deprescribing Tamsulosin in Older Men Phase 4
Recruiting NCT04853914 - Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound. N/A